Gilead's Q3 Bombshell: No More Hepatitis C R&D

Gilead's Q3 Bombshell: No More Hepatitis C R&D
Todd Campbell

Nov 2, 2016 at 4:41PM                    

Gilead Sciences (NASDAQ: GILD) is a Goliath in hepatitis C treatment; however, the company is shifting its research spending in the future away from hepatitis C to other indications, and that decision could have big implications on the hepatitis C market in the long term...  

Gilead Sciences' news could give AbbVie and Merck & Co. an opportunity to gain share if they continue developing new therapies that can compete better. AbbVie's ABT-493 plus ABT-530 mash-up, for example, is in late-stage studies that include an eight-week dosing option. If trials are successful, that therapy could compete more effectively against the short-duration Harvoni regimen in genotype 1...

Continue reading....